Different systems. Useful questions. | A question to investigate
US formulary review | A clearer argument deserves a clearer challenge
A formulary discussion needs more than a persuasive summary of a medicine. The committee has to see which evidence applies, what remains uncertain and what adoption would require in its own setting. We want a review process to make a strong argument easier to challenge, so clinical and operational decision-makers can distinguish an attractive proposition from one that survives scrutiny.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
A committee has a particular remit
A hospital committee, health-plan team and Medicare plan sponsor do not make identical decisions. The first brief would state the committee’s remit, population and decision authority. The buyer may be the pharmacy leader responsible for preparing material rather than the committee itself. The incentive is a more complete and efficient review, not a predetermined listing outcome or an automated recommendation to substitute one treatment for another.
Use the right policy frame
CMS formulary guidance provides Medicare-specific context (CMS, n.d.). It would not be applied indiscriminately to a hospital’s internal formulary or a commercial contract. We would identify which official documents are relevant and preserve their dates. Any local rule, exception process or implementation condition would need confirmation from the sponsor. The output should separate public policy context from the organisation’s own authorised procedure so readers can see what governs the decision.
A first pilot built around one question
We propose a controlled evidence-preparation exercise for a single committee question. Inputs could include an agreed question, a bounded set of publications, public policy documents and local implementation criteria. The comparator would be the current review method. Both methods would have the same source window and deadline. A qualified reviewer would check citations, population relevance, uncertainty and the completeness of implementation considerations.
Separate clinical evidence from affordability
A clinical result, a published price and a budget-impact assumption answer different questions. We would keep them in separate parts of the brief, with explicit source and perspective. The organisation would need to supply authorised local assumptions for a meaningful financial scenario. A public acquisition benchmark cannot establish the buyer’s net price. Any clinical comparison would remain subject to appropriate professional appraisal, including its applicability to the stated population.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
A US-facing medicines business, analyst or research team deciding whether a public spending comparison is meaningful.
The same medicine. A different denominator.
A spending figure becomes useful when the reader knows the programme, period, unit and exclusions behind it. Reconciliation comes before an attractive price comparison.
A proposition to investigate
A comparable question before a bigger chart.
A public-data brief could identify whether two measures describe sufficiently similar activity to compare. The proposed value is a traceable inclusion decision and a clear definition of the measure. No current price, negotiated saving, purchasing recommendation or live dataset calculation is produced in this specimen.
The reconciliation task is constructed. No records have been joined or analysed in this example.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether a defined public-data comparison is valid enough to commission.
- The comparator
- A second explicitly defined source with comparable scope, units and period.
- The evidence
- Source editions, medicine mapping, population, units, exclusions and reproducible inclusion rules.
- Stop or redesign
- Exclude comparisons when the denominator or cost meaning cannot be reconciled; retain the exclusion reason.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefMake the missing information productive
The output should explain what would change the committee’s confidence: a more relevant comparator, longer follow-up, a local resource estimate or clarification of an operational condition. We would retain negative findings and evidence that weakens the proposed case. Missing evidence would not be filled with plausible prose. A concise uncertainty register can be more valuable than a longer summary if it makes the next review task clear.
Evaluate the preparation, not the vote
Proposed measures include material omission rate, citation accuracy, reviewer effort and whether local implementation questions are visible. The committee’s eventual vote would not be a simple success metric for the software. A rejection can be the right decision, and a positive decision can still rely on evidence outside the pilot. We would report additional checking required so the apparent efficiency is not achieved by moving hidden work to senior reviewers.
What a commercial next step needs
We would stop if sources cannot be verified, the question exceeds available expertise or the method repeatedly conceals important uncertainty. Continuation would require a repeatable preparation need and evidence that reviewers find the output useful without losing control. A paid evaluation could then specify a bounded portfolio of questions. It would not promise formulary acceptance, payer endorsement or clinical validation of PHARMORIS itself.
Sources and reading context
Official source context checked on 13 October 2026. The study design above is a NEUVIOR proposal for discussion, not a reported deployment or result.
CMS (n.d.) Formulary Guidance. Available at: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/formulary-guidance (Accessed: 14 October 2026).
Discuss a committee evidence study
Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.
Another useful angle.
- US health plans | Make the medicines case explicit
Explore a proposed PHARMORIS evidence-preparation study for US health plans, separating benefit design, operational effort and accountable decision-making.
- Australia community pharmacy | Readiness, delivery and the work between
A proposed PHARMORIS evaluation for Australian community pharmacy services, grounded in local delivery and careful interpretation of PBS data.
- Australia hospital pharmacy | See the implementation behind the option
A proposed operational evidence study for Australian hospital pharmacy leaders, connecting implementation demands with accountable review and local data.